Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Steroid refractory acute graft-versus-host disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Steroid refractory acute graft-versus-host disease: Overview
Acute graft-versus-host disease (aGVHD) is a usual complication associated with allogeneic hematopoietic stem cell transplantation (alloHCT). This disease is a major cause of morbidity. Systemic steroid therapies are the standard first line therapy for aGVHD. However, 35-50% of patients with aGVHD become refractory to systemic steroid therapy. The disease develops in the skin, GI tract, and liver of the patients with alloHCT. Symptoms depend on the severity of aGVHD and include maculopapular rash, vomiting, nausea, abdominal cramps, watery diarrhea, and hyperbilirubinemia with jaundice.
“Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Steroid refractory acute graft-versus-host disease pipeline landscape is provided which includes the disease overview and Steroid refractory acute graft-versus-host disease treatment guidelines. The assessment part of the report embraces, in depth Steroid refractory acute graft-versus-host disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Steroid refractory acute graft-versus-host disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Steroid refractory acute graft-versus-host disease R&D. The therapies under development are focused on novel approaches to treat/improve Steroid refractory acute graft-versus-host disease.
Steroid refractory acute graft-versus-host disease Emerging Drugs Chapters
This segment of the Steroid refractory acute graft-versus-host disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Steroid refractory acute graft-versus-host disease Emerging Drugs
Itacitinib: Incyte Corporation
Incytes’ novel drug candidate, Itacitinib, is an orally administered small molecule in development for the treatment of steroid refractory aGVHD. The drug is a selective inhibitor of JAK-1 and given in combination with corticosteroids for treating acute as well as chronic aGVHD. The drug has received orphan drug status and has demonstrated good efficacy results in its phase II trial and currently undergoing phase 3 of clinical trials.
Glassia: Kamada
Kamada’s “lead” drug Glassia which is an immunomodulator as well as serine endopeptidase inhibitors molecule is currently being evaluated for the treatment of steroid refractory aGVHd snf has demonstrated good safety and efficacy profile in its earlier phase trials.
Further product details are provided in the report……..
Steroid refractory acute graft-versus-host disease : Therapeutic Assessment
This segment of the report provides insights about the different Steroid refractory acute graft-versus-host disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Steroid refractory acute graft-versus-host disease
There are approx. 10+ key companies which are developing the therapies for Steroid refractory acute graft-versus-host disease. The companies which have their Steroid refractory acute graft-versus-host disease drug candidates in the most advanced stage, i.e. phase III include, Incyte Corporation.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Steroid refractory acute graft-versus-host disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Steroid refractory acute graft-versus-host disease : Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Steroid refractory acute graft-versus-host disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Steroid refractory acute graft-versus-host disease drugs.
Steroid refractory acute graft-versus-host disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Steroid refractory acute graft-versus-host disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Steroid refractory acute graft-versus-host disease: Overview
Acute graft-versus-host disease (aGVHD) is a usual complication associated with allogeneic hematopoietic stem cell transplantation (alloHCT). This disease is a major cause of morbidity. Systemic steroid therapies are the standard first line therapy for aGVHD. However, 35-50% of patients with aGVHD become refractory to systemic steroid therapy. The disease develops in the skin, GI tract, and liver of the patients with alloHCT. Symptoms depend on the severity of aGVHD and include maculopapular rash, vomiting, nausea, abdominal cramps, watery diarrhea, and hyperbilirubinemia with jaundice.
“Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Steroid refractory acute graft-versus-host disease pipeline landscape is provided which includes the disease overview and Steroid refractory acute graft-versus-host disease treatment guidelines. The assessment part of the report embraces, in depth Steroid refractory acute graft-versus-host disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Steroid refractory acute graft-versus-host disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Steroid refractory acute graft-versus-host disease R&D. The therapies under development are focused on novel approaches to treat/improve Steroid refractory acute graft-versus-host disease.
Steroid refractory acute graft-versus-host disease Emerging Drugs Chapters
This segment of the Steroid refractory acute graft-versus-host disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Steroid refractory acute graft-versus-host disease Emerging Drugs
Itacitinib: Incyte Corporation
Incytes’ novel drug candidate, Itacitinib, is an orally administered small molecule in development for the treatment of steroid refractory aGVHD. The drug is a selective inhibitor of JAK-1 and given in combination with corticosteroids for treating acute as well as chronic aGVHD. The drug has received orphan drug status and has demonstrated good efficacy results in its phase II trial and currently undergoing phase 3 of clinical trials.
Glassia: Kamada
Kamada’s “lead” drug Glassia which is an immunomodulator as well as serine endopeptidase inhibitors molecule is currently being evaluated for the treatment of steroid refractory aGVHd snf has demonstrated good safety and efficacy profile in its earlier phase trials.
Further product details are provided in the report……..
Steroid refractory acute graft-versus-host disease : Therapeutic Assessment
This segment of the report provides insights about the different Steroid refractory acute graft-versus-host disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Steroid refractory acute graft-versus-host disease
There are approx. 10+ key companies which are developing the therapies for Steroid refractory acute graft-versus-host disease. The companies which have their Steroid refractory acute graft-versus-host disease drug candidates in the most advanced stage, i.e. phase III include, Incyte Corporation.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Steroid refractory acute graft-versus-host disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
- Molecule Type
- Monoclonal Antibody
- Peptides
- Small molecule
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Steroid refractory acute graft-versus-host disease : Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Steroid refractory acute graft-versus-host disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Steroid refractory acute graft-versus-host disease drugs.
Steroid refractory acute graft-versus-host disease Report Insights
- Steroid refractory acute graft-versus-host disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Steroid refractory acute graft-versus-host disease drugs?
- How many Steroid refractory acute graft-versus-host disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Steroid refractory acute graft-versus-host disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Steroid refractory acute graft-versus-host disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Steroid refractory acute graft-versus-host disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Incyte Corporation
- Kamada
- Medac
- ElsaLys Biotech
- Pfizer
- Itacitinib
- Glassia
- MC0518
- Inolimomab
- Etanercept
Introduction
Executive Summary
Steroid refractory acute graft-versus-host disease : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Steroid refractory acute graft-versus-host disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Steroid refractory acute graft-versus-host disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Steroid refractory acute graft-versus-host disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Itacitinib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Glassia: Kamada
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Steroid refractory acute graft-versus-host disease Key Companies
Steroid refractory acute graft-versus-host disease Key Products
Steroid refractory acute graft-versus-host disease - Unmet Needs
Steroid refractory acute graft-versus-host disease - Market Drivers and Barriers
Steroid refractory acute graft-versus-host disease - Future Perspectives and Conclusion
Steroid refractory acute graft-versus-host disease Analyst Views
Steroid refractory acute graft-versus-host disease Key Companies
Appendix
Executive Summary
Steroid refractory acute graft-versus-host disease : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Steroid refractory acute graft-versus-host disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Steroid refractory acute graft-versus-host disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Steroid refractory acute graft-versus-host disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Itacitinib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Glassia: Kamada
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Steroid refractory acute graft-versus-host disease Key Companies
Steroid refractory acute graft-versus-host disease Key Products
Steroid refractory acute graft-versus-host disease - Unmet Needs
Steroid refractory acute graft-versus-host disease - Market Drivers and Barriers
Steroid refractory acute graft-versus-host disease - Future Perspectives and Conclusion
Steroid refractory acute graft-versus-host disease Analyst Views
Steroid refractory acute graft-versus-host disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Steroid refractory acute graft-versus-host disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Steroid refractory acute graft-versus-host disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Steroid refractory acute graft-versus-host disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Steroid refractory acute graft-versus-host disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
